Vitalea, Accium Collaborate to Cross-validate AMS Platform | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bioanalytical contract services firms Vitalea Sciences and Accium BioSciences today announced an agreement to cross-validate each other's' accelerator mass spectrometry platform.

The companies said successful completion of the studies "will permit delivery of bioanalytical services supported by backup AMS instrumentation operating under a unified and validated framework."

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.